The Current State of Artificial Intelligence for Benign Prostatic Hyperplasia.
1/5 보강
We review recent literature on the use of artificial intelligence (AI) for benign prostate hyperplasia (BPH).
APA
Murad L, Layne E, et al. (2025). The Current State of Artificial Intelligence for Benign Prostatic Hyperplasia.. European urology focus, 11(6), 999-1003. https://doi.org/10.1016/j.euf.2025.07.004
MLA
Murad L, et al.. "The Current State of Artificial Intelligence for Benign Prostatic Hyperplasia.." European urology focus, vol. 11, no. 6, 2025, pp. 999-1003.
PMID
40713289 ↗
Abstract 한글 요약
We review recent literature on the use of artificial intelligence (AI) for benign prostate hyperplasia (BPH). Many researchers have explored application of AI-based technologies for diagnosis and management of disease, prediction of treatment responses, and optimization of surgery and workflows. The latest research in urology is replete with AI-focused studies. However, AI applications in BPH have not been well established. Although many researchers have started to touch on key areas of interest, further research is necessary to fully elucidate the potential benefits of AI for patients with BPH. The development and implementation of standardized guidelines for model reporting and external validation are essential prerequisites for widespread adoption of AI within urology and across medicine in general. PATIENT SUMMARY: This mini review looks at how artificial intelligence AI) may help doctors in treating men with a large prostate gland. AI tools may help in picking treatments, improving surgery, and helping doctors to work faster, but not enough is known yet. More studies are needed before these tools can be routinely used to help patients.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.